Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-08-20 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a formal 'Company Announcement' issued by Genmab regarding a specific regulatory event: the U.S. FDA approval of a drug (DARZALEX) in combination with other therapies. It follows the standard format of a corporate press release/regulatory announcement, detailing the approval, the clinical studies (CANDOR, EQUULEUS), and the implications for the company's product portfolio. It does not constitute a full financial report, audit, or proxy statement, but rather a specific regulatory update announcement. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2020-08-20 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX®..." and is explicitly labeled as a "Company Announcement." It details a specific regulatory event (FDA approval) for a drug, which is a form of material information release. This type of announcement, focusing on a significant business development (drug approval) rather than routine financial reporting (like 10-K or ER), often falls under general regulatory announcements or specific corporate news. Since there is no specific category for 'Drug Approval Announcement,' and it is a formal, material announcement, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard filings. It is not an Earnings Release (ER), Interim Report (IR), or a proxy statement (DEF 14A/PSI). Given the nature of the announcement, RNS is the most appropriate general classification.
2020-08-20 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Genmab Announces Plan to Transition Arzerra®...' and is explicitly labeled as a 'Company Announcement'. It details a strategic business decision (transitioning a drug to an access program) and includes an immediate financial impact (USD 30 million payment) leading to an improved 2020 financial guidance outlook. This type of announcement, which communicates significant business events, strategic changes, or material updates outside of routine periodic financial reports (like 10-K or IR), often falls under general regulatory announcements or specific corporate actions. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A), it best fits the category for general regulatory announcements or corporate news. Given the content is a specific corporate action/update, and not a standard financial filing, 'Regulatory Filings' (RNS) serves as the most appropriate general category for material, non-standardized corporate news releases, especially when other specific codes like M&A (TAR) or Capital Change (CAP) do not perfectly apply to a drug access program change. The document length is substantial (9557 chars), so it is not an RPA.
2020-08-20 English
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding a change in the availability of a drug (Arzerra) and an update to their 2020 financial guidance. While it contains financial guidance, it is not a full quarterly or annual report, but rather a specific corporate announcement regarding operational changes and a one-time payment. It fits the definition of a general regulatory announcement (RNS) as it is a corporate press release/announcement issued to the market.
2020-08-20 English
6-K
Foreign Filer Report
2020-08-20 English
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the U.S. FDA approval of a drug (Kesimpta). It provides details on the clinical trials (ASCLEPIOS, APLIOS), the nature of the drug, and the impact on the company. It does not fit into specific financial reporting categories like 10-K, ER, or IR, nor is it a report publication announcement (it is the announcement itself). Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2020-08-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.